Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
City of Hope Medical Center
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
University of Wisconsin, Madison
BeOne Medicines
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Astellas Pharma Inc
Bristol-Myers Squibb
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Bristol-Myers Squibb
Rutgers, The State University of New Jersey
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Mayo Clinic
Hoffmann-La Roche
M.D. Anderson Cancer Center
Bristol-Myers Squibb
SWOG Cancer Research Network
Nationwide Children's Hospital
Duke University
NRG Oncology
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
BeiGene
Hoffmann-La Roche
AbbVie
BeiGene
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
University of California, San Diego
American Regent, Inc.
Leap Therapeutics, Inc.
BeiGene
Tesaro, Inc.
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
University of Kentucky
Mayo Clinic
Merck Sharp & Dohme LLC